Clinical trials: Colorectal Neoplasms, Hereditary Nonpolyposis
Colorectal Cancer
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients for 2 years.
- Trial name
- MesaCAPP (NCT03070574)
- Testing
- mesalamine 2400 MG (5-ASA), mesalamine 1200 MG
- Where
- 6 sites in Austria, Germany and 4 more
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Christoph Gasche
Lynch Syndrome
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
Lynch syndrome (LS) is the most common genetic predisposition syndrome for colorectal cancer (CRC), responsible for around 2-4% of cancers.
- Trial name
- CADLYNCH (NCT05963191)
- Testing
- Colorectal cancer screening with CAD EYE colonoscopy
- Where
- France
- Volunteers
- 272 people
- Sponsor
- PERROD Guillaume
Familial Pancreatic Cancer, BRCA1 Mutation
Registry of Subjects at Risk of Pancreatic Cancer
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
- Conditions
- Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation, Lynch Syndrome
- Trial name
- IRFARPC (NCT04095195)
- Testing
- MRCP, Endoultrasonography
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
Lynch Syndrome
The Yield of Artificial Intelligence (GI Genius) in Lynch Syndrome - A Randomized Tandem-colonoscopy Trial
We aim to investigate the incremental detection rate of polyps using AI- assisted colonoscopy compared with high-definition white-light endoscopy (HD-WLE).
- Trial name
- NCT06654128
- Testing
- artificial intelligence
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Lynch Syndrome
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria
The purpose of this study is to find out the proportion of patients diagnosed with Lynch syndrome in colorectal cacner patients meeting Chinese Lynch syndrome criteria.
- Trial name
- NCT03046849
- Testing
- next-generation sequencing
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lynch Syndrome, Hereditary Colonic Polyposis Syndromes
Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes
The purpose of this study is to understand the role bacteria that normally live in the colon may play in colorectal cancer risk, in addition to the hereditary risk to colorectal cancer.
- Trial name
- NCT02371135
- Testing
- colonic biopsies, questionnaires
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Breast Cancer
Clinical Validation of Sophia Genetics Assay
Next-generation sequencing (NGS) technologies have revolutionized the field of genomics, enabling rapid and cost-effective analysis of DNA and RNA .
- Conditions
- Ovarian Cancer, Breast Cancer, Lynch Syndrome, Intestinal Polyposis
- Trial name
- COSMOS (NCT07160010)
- Testing
- Sophia Herditary Cancer Solution
- Volunteers
- 248 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gynecologic Cancer, Ovary Cancer
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome.
- Conditions
- Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer
- Trial name
- NCT05677048
- Testing
- Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group
- Where
- United States
- Volunteers
- 205 people
- Sponsor
- M.D. Anderson Cancer Center
Hereditary Cancer Syndrome
Cancer Health Assessments Reaching Many
The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations.
- Trial name
- CHARM (NCT03426878)
- Testing
- Modified genetic counseling, Traditional genetic counseling
- Where
- 2 sites in United States
- Volunteers
- 967 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Lynch Syndrome, Lynch Syndrome I
Videocapsule Endoscopy in Lynch Syndrome
Background Lynch syndrome is caused by a pathogenic variant in one of the four Mismatch Repair genes (MMR): MLH1, MSH2/Epcam, MSH6, or PMS2.
- Conditions
- Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, MLH1 Gene Mutation
- Trial name
- NCT05704010
- Testing
- Video capsule endoscopy
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Lynch Syndrome
First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers
Tha aim of this clinical trial is to evaluate safety and tolerability of autologous peripheral blood differentiated and matured adult dendritic cells. Immunogenicity of the prduct(DC-DELAY) will be evaluated also.
- Trial name
- DELAY (NCT07163403)
- Testing
- Autologous Tolerogenic Dendritic cells
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Colorectal Cancer, Lynch Syndrome
Molecular Screening for Lynch Syndrome in Southern Denmark
A clinically applicably strategy for molecular screening for Lynch Syndrome has been implemented in the Region of Southern Denmark.
- Conditions
- Colorectal Cancer, Lynch Syndrome, HNPCC
- Trial name
- NCT01216930
- Testing
- Observation
- Where
- 7 sites in Denmark
- Volunteers
- 2,000 people
- Sponsor
- Vejle Hospital
Li Fraumeni Syndrome, Lynch Syndrome
Inherited Cancer Early Diagnosis (ICED) Study
ICED is a prospective sample collection research study, aiming to develop or validate a blood/urine biomarker which could potentially detect cancers early in individuals at high risk of developing cancers, due to certain germline…
- Conditions
- Li Fraumeni Syndrome, Lynch Syndrome, Hereditary Diffuse Gastric Cancer, Cowden Syndrome
- Trial name
- ICED (NCT06163365)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Lynch Syndrome
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer
The purpose of this study is to determine the proportion of patients diagnosed with Lynch syndrome in colorectal cancer patients with the loss of staining by immunohistochemistry (IHC) of any of the mismatch repair (MMR)…
- Trial name
- NCT03047226
- Testing
- next-generation sequencing
- Where
- 7 sites in China
- Volunteers
- 311 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Carcinoma, Colorectal Neoplasm
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome.
- Conditions
- Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
- Trial name
- NCT05419011
- Testing
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 186 people
- Sponsor
- National Cancer Institute (NCI)
Lynch Syndrome
Overcoming Barriers to Uptake of Cascade Screening
Lynch syndrome is a genetic condition that increases cancer risk. The public health impact of genetic testing for disease prevention hinges on cascade screening, which is the systematic identification and testing of blood…
- Trial name
- NCT07304063
- Testing
- Let's Talk Genetics Providers, Let's Talk Patients
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Carcinoma, Lynch Syndrome
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
This phase Ib/II trial evaluates the safety and effect of the Nous-209 vaccine in Lynch syndrome patients. Lynch syndrome is an inherited disorder in which affected individuals have a higher-than-normal chance of developing…
- Trial name
- NCT05078866
- Testing
- Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Cancer Gene Mutation, Lynch Syndrome
Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation
The objective of the study is the provide proof of high correlation between somatic and germline mismatch repair instability. This correlation is specifically researched in an area where patients have less access to cancer…
- Conditions
- Cancer Gene Mutation, Lynch Syndrome, Endometrial Cancer, Somatic Mutation
- Trial name
- NCT04516083
- Testing
- Mismatch repair instability somatic and germline testing
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- RWJ Barnabas Health at Jersey City Medical Center
Lynch Syndrome
Multi-Organ Screening Recommendations in Patients With Lynch Syndrome
The purpose of this study is to examine how people with a family history of colon cancer and other related cancers respond to recommendations for cancer screening after genetic counseling.
- Trial name
- NCT00582296
- Testing
- questionnaires, telephone interview, optional blood drawn, questionnaires, telephone interview and optional blood drawn
- Where
- 8 sites in United States
- Volunteers
- 1,530 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lynch Syndrome
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
The proposed trial will evaluate the effect of aspirin 300 mg/d and 100 mg/d during 4 years vs placebo, in a 4 groups randomised parallel design in Lynch syndrome patients: patients with proven carriers of pathological mutations…
- Trial name
- AAS-Lynch (NCT02813824)
- Testing
- Acetylsalicylic acid lysinate 300 mg, Acetylsalicylic acid lysinate 100 mg
- Where
- France
- Volunteers
- 852 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris